Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M. Taverna C, et al. Among authors: vanazzi a. J Clin Oncol. 2016 Feb 10;34(5):495-500. doi: 10.1200/JCO.2015.61.3968. Epub 2015 Dec 28. J Clin Oncol. 2016. PMID: 26712227 Free PMC article. Clinical Trial.
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
Mazzara S, Travaini L, Botta F, Granata C, Motta G, Melle F, Fiori S, Tabanelli V, Vanazzi A, Ramadan S, Radice T, Raimondi S, Lo Presti G, Ferrari ME, Jereczek-Fossa BA, Tarella C, Ceci F, Pileri S, Derenzini E. Mazzara S, et al. Among authors: vanazzi a. Blood Adv. 2023 Feb 28;7(4):630-643. doi: 10.1182/bloodadvances.2022007825. Blood Adv. 2023. PMID: 36806558 Free PMC article.
High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.
Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, Ferrari M, Radice D, Papi S, Martinelli G, Paganelli G. Ferrucci PF, et al. Among authors: vanazzi a. Br J Haematol. 2007 Nov;139(4):590-9. doi: 10.1111/j.1365-2141.2007.06869.x. Br J Haematol. 2007. PMID: 17979944 Free article.
Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
Laszlo D, Pruneri G, Andreola G, Radice D, Calabrese L, Rafaniello PR, Nassi L, Sammassimo S, Alietti A, Agazzi A, Vanazzi A, Martinelli G. Laszlo D, et al. Among authors: vanazzi a. Int J Surg Pathol. 2011 Aug;19(4):417-24. doi: 10.1177/1066896909345596. Epub 2009 Sep 30. Int J Surg Pathol. 2011. PMID: 19793830
Rituximab in Hodgkin lymphoma: is the target always a hit?
Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA. Saini KS, et al. Among authors: vanazzi a. Cancer Treat Rev. 2011 Aug;37(5):385-90. doi: 10.1016/j.ctrv.2010.11.005. Epub 2010 Dec 22. Cancer Treat Rev. 2011. PMID: 21183282 Review.
39 results